Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| A&E | Accident and emergency |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AJCC | American Joint Committee on Cancer |
| ALCL | Anaplastic large cell lymphoma |
| ALK | Anaplastic lymphoma kinase |
| ASCO | American Society of Clinical Oncology |
| ASTCT | American Society for Transplantation and Cellular Therapy |
| ATC | Anatomical Therapeutic Chemical |
| BCRP | Breast cancer resistance protein |
| BICR | Blinded independent central review |
| BID | Twice daily |
| c-Met | Hepatocyte growth factor receptor |
| C1D15 | Cycle 1, day 15 |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COVID-19 | Coronavirus disease 2019 |
| CPT | Current Procedural Terminology |
| CR | Complete response |
| CTLA4 | Cytotoxic T-lymphocyte-associated protein 4 |
| CYP | Cytochrome P450 |
| CYP3A | Cytochrome P450 3A |
| CYP3A4/5 | Cytochrome P450 3A4 and 3A5 |
| DeCOG | Dermatologic Cooperative Oncology Group |
| DNA | Deoxyribonucleic acid |
| ECG | Electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| EMA | European Medicines Agency |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EQ-5D | EuroQol 5-dimension instrument |
| EQ-5D-3L | EuroQol 5-dimension 3-level instrument |
| EQ-5D-5L | EuroQol 5-dimension 5-level instrument |
| ESMO | European Society for Medical Oncology |
| EU | European Union |
| EURACAN | European Reference Network for Rare Adult Solid Cancers |
| FACT-G | Functional Assessment of Cancer Therapy-General |
| FDA | Food and Drug Administration |
| G-BA | Federal Joint Committee (Gemeinsamer Bundesausschuss) |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HES | Hospital Episode Statistics |
| HLA | Human leukocyte antigen |
| HLA-A2 | Human leukocyte antigen A2 |
| ICER | Incremental cost-effectiveness ratio |
| ICU | Intensive care unit |
| ID | Identifier |
| IHP | Isolated hepatic perfusion |
| IMT | Inflammatory myofibroblastic tumor |
| IRT | Interactive response technology |
| LDH | Lactate dehydrogenase |
| M-PHP | Percutaneous hepatic perfusion with melphalan |
| MAPK | Mitogen-activated protein kinase |
| MEK | Mitogen-activated protein kinase kinase |
| MET | Mesenchymal-epithelial transition factor |
| MIPS | Merit-based Incentive Payment System |
| mRNA | Messenger ribonucleic acid |
| mUM | Metastatic uveal melanoma |
| NAACCR | North American Association of Central Cancer Registries |
| NCCN | National Comprehensive Cancer Network |
| NCI | National Cancer Institute |
| NDA | New Drug Application |
| NDC | National Drug Code |
| NHS | National Health Service |
| NHSE | National Health Service England |
| NICE | National Institute for Health and Care Excellence |
| NSCLC | Non-small cell lung cancer |
| NYHA | New York Heart Association |
| ORR | Objective response rate |
| OS | Overall survival |
| P-gp | P-glycoprotein |
| PD | Progressive disease |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PDQ | Physician Data Query |
| PFS | Progression-free survival |
| PHP | Percutaneous hepatic perfusion |
| PI3K | Phosphoinositide 3-kinase |
| PKC | Protein kinase C |
| pMARCKS | Phosphorylated myristoylated alanine-rich C-kinase substrate |
| pPKC | Phosphorylated protein kinase C |
| PR | Partial response |
| PS | Performance status |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| QLQ-C30 | Quality of Life Questionnaire Core 30 |
| QTcF | QT interval corrected for heart rate by the Fridericia method |
| RDE | Recommended dose for expansion |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| REMS | Risk Evaluation and Mitigation Strategy |
| RON | Recepteur d'origine nantais |
| ROS1 | ROS proto-oncogene 1, receptor tyrosine kinase |
| RTOR | Real-Time Oncology Review |
| SD | Stable disease; standard deviation |
| SEER | Surveillance, Epidemiology, and End Results |
| SMR | Society for Melanoma Research |
| TCGA | The Cancer Genome Atlas |
| TEBE | Tebentafusp |
| TRAE | Treatment-related adverse event |
| ULN | Upper limit of normal |
| US | United States |
| USA | United States of America |
| USCS | United States Cancer Statistics |
| WHO | World Health Organization |